Japanese study to evaluate the utility of eribulin dose and schedule in treatment for advanced breast cancer patients(JUST-STUDY)-additional research on patients enrolled in JUST-STUDY-

Japanese study to evaluate the utility of eribulin dose and schedule in treatment for advanced breast cancer patients(JUST-STUDY)-additional research on patients enrolled in JUST-STUDY- - Japanese study to evaluate the utility of eribulin dose and schedule in treatment for advanced breast cancer patients(JUST-STUDY)-additional research on patients enrolled in JUST-STUDY-

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000019137

Enrollment

Registered

2015-09-28

Start date

2015-09-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: All who enrolled in JUST-STUDY

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Time to Treatment Failure(TTF) of bi-weekly patients	—

Secondary

Measure	Time frame
Overall survival(OS), safety	—

Countries

Japan

Contacts

Public ContactJUST-STUDY Executive Office

NPO Advanced Clinical Reserch Organization JUST-STUDY Executive Office

eriburlin-study@npo-acro.jp042-352-7676

Outcome results